Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Outcomes of Degenerative Disc Disease Patients Treated With an Anterior-Only Fusion Using InQu Bone Graft

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by Kansas Joint and Spine Institute
Sponsor:
Collaborators:
National Center of Innovation for Biomaterials in Orthopaedic Research
ISTO Technologies, Inc.
Information provided by (Responsible Party):
Mark Camden Whitaker, Kansas Joint and Spine Institute
ClinicalTrials.gov Identifier:
NCT01746212
First received: December 3, 2012
Last updated: December 6, 2012
Last verified: December 2012
  Purpose

The purpose of this study is to report the radiographic, clinical, and functional outcomes of a consecutive series of patients diagnosed with single or bilateral degenerative disc disease between L4 and S1, that have been treated with an anterior lumbar interbody fusion (ALIF), anterior only surgical approach, and InQu Bone Graft Extender and Substitute for bony fusion and instrumentation.

Patients that decide to undergo an Anterior Lumbar Interbody Fusion (ALIF) surgery [a surgical procedure that joins two or more lumbar vertebrae (small bones of the spine) together into one solid bony structure by approaching the spine through the abdomen (front of the body) and placing a bone graft in between the vertebral bodies where the disc usually lies], are invited to participate in an orthopaedic research study.

This study will compare patients that have been treated with an anterior lumbar interbody fusion using InQu Bone Graft Extender & Substitute to published data for a stand alone spinal fusion surgery, where InFuse bone graft is placed between the transverse processes [small bony projections off the right and left side of each bone in your spine] of the affected vertebrae.

X-rays, daily activities, and how patients are doing will be evaluated at specific time points during this study.

The hypothesis of this study is that patients diagnosed with degenerative disc disease treated with an anterior lumbar interbody fusion, anterior only surgical approach (incision through the abdomen), using InQu Bone Graft Extender and Substitute and instrumented fixation have comparable radiographic (x-rays), functional (daily activities), and clinical (how the patient is doing) outcomes when compared to published data for use of InFuse in stand-alone fusion.


Condition Intervention
Degenerative Disc Disease
Procedure: One-level or two-level anterior lumbar interbody fusion
Biological: InQu Bone Graft Extender and Substitute mixed with BMAC
Device: Synthes Spinal Instrumentation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Outcomes of Patients With Lumbar Degenerative Disc Disease Treated Operatively With an Anterior-Only Approach Using InQu Bone Graft Extender and Substitute

Resource links provided by NLM:


Further study details as provided by Kansas Joint and Spine Institute:

Primary Outcome Measures:
  • Evidence of successful radiographic fusion at 1-year post-operative [ Time Frame: 12-months post-operative ] [ Designated as safety issue: No ]

    X-rays and CTs will be analyzed for fusion based on the following criteria:

    1. Bridging trabecular bone connecting the two vertebral bodies either through the dowels or around the dowels as evaluated by thin-cut CT scans and radiographs;
    2. No angular motion of 5 degrees or more on dynamic plain radiographs;
    3. No sagittal translation of more than 3 mm on dynamic plain radiographs; and
    4. No radiolucencies that involve more than half of the interfaces between the dowels and the host vertebral end plates.

    Criteria is based on the Burkus, Transfelt, et. al study titled "Clinical and Radiographic Outcomes of Anterior Lumbar Interbody Fusion Using Recombinant Human Bone Morphogenetic Protein-2."



Secondary Outcome Measures:
  • Improvement in Oswestry Disability Index Score (1-year) [ Time Frame: Change from baseline to 12-months post-operative ] [ Designated as safety issue: No ]
    Change in ODI and between baseline and 1-year post-operative, anticipating improvement in ODI score (i.e. from baseline to 12-months post-operative, scores should decrease).

  • Improvement in Oswestry Disability Index Scores (2-years) [ Time Frame: Change from baseline to 24-month post-operative ] [ Designated as safety issue: No ]
    Change in ODI and between baseline and 2-year post-operative, anticipating improvement in ODI score (i.e. from baseline to 24-months post-operative, scores should decrease).

  • Improvement in Visual Analog Scale Scores (1-year) [ Time Frame: Change from baseline to 12-months post-operative ] [ Designated as safety issue: No ]
    Change in VAS and between baseline and 1-year post-operative, anticipating improvement in VAS score (i.e. from baseline to 12-months post-operative, scores should decrease).

  • Improvement in Visual Analog Scale Scores (2-years) [ Time Frame: Change from baseline to 24-months post-operative ] [ Designated as safety issue: No ]
    Change in VAS and between baseline and 2-year post-operative, anticipating improvement in VAS score (i.e. from baseline to 24-months post-operative, scores should decrease).


Other Outcome Measures:
  • Surgical Outcomes [ Time Frame: At time of surgery ] [ Designated as safety issue: No ]
    Estimated blood loss, Operative time, Hospital stay

  • Radiographic Measurements at 6-months post-operative [ Time Frame: Change from baseline to 6-months post-operative ] [ Designated as safety issue: No ]
    Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density

  • Radiographic Measurements at 12-months post-operative [ Time Frame: Change from baseline to 12-months post-operative ] [ Designated as safety issue: No ]
    Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density

  • Radiographic Measurements at 18-months post-operative [ Time Frame: Change from baseline to 18-months post-operative ] [ Designated as safety issue: No ]
    Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density

  • Radiographic Measurements at 24-months post-operative [ Time Frame: Change from baseline to 24-months post-operative ] [ Designated as safety issue: No ]
    Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density


Estimated Enrollment: 60
Study Start Date: December 2012
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Degenerative Disc Disease
Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
Procedure: One-level or two-level anterior lumbar interbody fusion
Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
Other Name: ALIF
Biological: InQu Bone Graft Extender and Substitute mixed with BMAC
Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
Other Names:
  • InQu
  • BMAC
  • SmartPRep2 centrifuge
Device: Synthes Spinal Instrumentation
Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
Other Names:
  • ATB Plate
  • Peek Cage
  • SynFix-LR

Detailed Description:

This is a prospective, observational study; evaluating outcomes of patients that have elected to receive surgical intervention in order to treat degenerative disc disease. In order to be eligible for enrollment into this study, patients have already elected to be treated with an anterior lumbar interbody fusion, an anterior only approach for single or bi-level degenerative disc disease between L4 and S1 with instrumented fusion, using a combination of InQu Bone Graft Extender and Substitute, local bone, and Bone Marrow Aspirate Concentrate (BMAC) to promote bony fusion. Only after the patient and physician determine the surgical procedure, can the patient be eligible for enrollment. A consecutive series of 60 patients will be offered enrollment if all inclusion/exclusion criteria are met.

Data will be collected by chart review to include pre-operative, surgical, functional, post-operative, and radiographic imaging charted data, collected as part of the routine clinical visit, and standard of care.

Follow-up data will include newly charted clinical, functional, and radiographic imaging data, including dynamic x-rays and CT scans to be obtained prospectively at a minimum of one (1) year post-operatively. During the routine post-surgical visits, patient pain outcomes are measured using the Visual Analog Scale (VAS) for back and leg pain, function is measured by the Oswestry Disability Index (ODI) and Short Form-12 Version 2 (SF-12 Version 2 Health Survey). A physician investigator will also perform routine clinical evaluations.

The patients will undergo standard radiographic procedures to obtain x-rays (including lateral, anterior-posterior, and dynamic flexion/extension) as part of the standard of care. A CT scan will be performed for research purposes as indicated in the protocol follow-up procedure. X-rays and CT scans will be evaluated by an independent radiologist and a physician investigator to determine anterior fusion status and the status of the anterior hardware constructs.

The National Center of Innovation for Biomaterials in Orthopaedic Research and Medical Metric, Inc. will assist with imaging analysis of x-rays and CTs.

ISTO Technologies, Inc. will be providing a grant to cover costs associated with the research components of this study.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Target population included adult patients from the normal patient population seen at Kansas Joint and Spine Institute, currently also known as Kansas Spine Specialists, that have the ability to provide informed consent without assistance. Each patient that is qualified for an anterior lumbar interbody fusion, with an anterior only approach, will be offered the InQu Bone Graft Extender and Substitute as the bone graft the investigator will use in surgery. Patients that proceed with surgical intervention, and that meet all inclusion/exclusion criteria, will be offered enrollment into the study.

Criteria

Inclusion Criteria: Patients are eligible for this study if the following criteria are all met.

  • Patient will be surgically treated with an anterior lumbar interbody fusion, anterior only approach by one of the listed physician investigators
  • Must have had a structural problem potentially amendable to primary fusion at one or two levels
  • InQu Bone Graft Extender and Substitute will be used in the surgery
  • Had failed conservative care for longer than three (3) months
  • Had no psychological contraindications for surgery
  • Aged 18 to 70 years of age at the time of surgery

Exclusion Criteria: Patients are ineligible for this study if any one of the following criteria apply.

  • Patients that will not be surgically treated with an anterior lumbar interbody fusion, anterior only approach by one of the physician investigators
  • InQu Bone Graft Extender and Substitute will not be used in the surgery
  • Patient carries any one of the following diagnoses: spinal stenosis requiring decompression, isthmic spondylolisthesis, degenerative spondylolisthesis greater than three (3) millimeters, three or more degenerative levels, major deformity, have had a previous lumbar fusion, or if they have had a previous infection or tumor
  • Individuals that can not provide consent for themselves
  • Patients requiring revision surgery
  • Aged younger than 18 or older than 70 at the time of surgery
  • Patients will be excluded from participating in the study if, in the investigators' opinion, they will be unable to comply with study procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01746212

Contacts
Contact: Jennifer Duong 316-858-1900 ext 110 jduong@kjsi.com

Locations
United States, Kansas
Kansas Joint and Spine Institute Recruiting
Wichita, Kansas, United States, 67226
Contact: Jennifer Duong, BA    316-858-1900 ext 110    jduong@kjsi.com   
Contact: Mark C. Whitaker, MD    316-858-1900    cwhitaker@kjsi.com   
Principal Investigator: Mark C. Whitaker, MD         
Sub-Investigator: John Lammli, MD         
Sub-Investigator: Alan Moskowitz, MD         
Sub-Investigator: Brent Adams, MD         
Sub-Investigator: Kris Lewonowski, MD         
Sub-Investigator: Jennifer Duong, BA         
National Center of Innovation for Biomaterials in Orthopaedic Research Active, not recruiting
Wichita, Kansas, United States, 67226
Sponsors and Collaborators
Kansas Joint and Spine Institute
National Center of Innovation for Biomaterials in Orthopaedic Research
ISTO Technologies, Inc.
Investigators
Principal Investigator: Mark C Whitaker, MD Kansas Joint and Spine Institute
  More Information

No publications provided

Responsible Party: Mark Camden Whitaker, Principal Investigator, Kansas Joint and Spine Institute
ClinicalTrials.gov Identifier: NCT01746212     History of Changes
Other Study ID Numbers: InQu ALIF
Study First Received: December 3, 2012
Last Updated: December 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Kansas Joint and Spine Institute:
Degenerative Disc Disease
InQu Bone Graft Extender and Substitute
Anterior Lumbar Interbody Fusion
Oswestry Disability Index
Visual Analog Scale
Stand-alone ALIF
Bone Marrow Aspirate Concentrate
Fusion rate
Disc Height
Mean Optical Density
Integrated Optical Density

Additional relevant MeSH terms:
Intervertebral Disc Degeneration
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on November 27, 2014